Myriad Genetics Gets a Hold Rating from Cowen & Co.

By Carrie Williams

In a report issued on September 15, Doug Schenkel from Cowen & Co. reiterated a Hold rating on Myriad Genetics (NASDAQ: MYGN), with a price target of $25. The company’s shares closed on Friday at $32.87, close to its 52-week high of $33.42.

According to TipRanks.com, Schenkel is a 5-star analyst with an average return of 8.3% and a 68.8% success rate. Schenkel covers the Healthcare sector, focusing on stocks such as Becton Dickinson, Oxford Immunotec, and NanoString Tech.

Currently, the analyst consensus on Myriad Genetics is Hold and the average price target is $22.83, representing a -30.5% downside.

In a report issued on September 12, Jefferies also reiterated a Hold rating on the stock with a $23 price target.

Myriad Genetics’ market cap is currently $2.25B and has a P/E ratio of 102.72. The company has a book value ratio of 2.8891.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through two segments: Diagnostics and Other.